CLDN18 and neoplasm: In the randomized phase II FAST trial, zolbetuximab in combination with the primary chemotherapy regimen epirubicin, oxaliplatin, and capecitabine (EOX) was associated with significantly better PFS (HR: 0.44, 95% CI: 0.29–0.67; p < 0.0005) and OS (HR: 0.55, 95% CI: 0.39–0.77; p < 0.0005) compared to EOX alone in G/GEJ cancer patients with moderate to strong CLDN18.2 expression in at least 40% of tumor cells.